📢 ** Published on April 30, 2024**
Researchers from McGill University in Montreal conducted a comprehensive study involving 128 clinical trials. In this study, there were two groups of patients:
**Research Group**: Received the new investigational drugs.
** Control Group**: Received the standard conventional treatment.
A total of 47,050 cancer patients participated in the study. The findings were remarkable:
** Significant reduction in disease progression risk**: Patients who received the investigational drug showed a lower risk of disease progression compared to the control group that received standard treatment.
** Significant increase in life expectancy**: The life expectancy of patients who received the investigational drug also increased significantly.
**🔗 Link to the original article https://www.acpjournals.org/doi/10.7326/M23-2515 **
📣 **Inspiring Success Stories** 📣
Take, for example, Jerri, who was diagnosed with stage 4 inflammatory breast cancer in 2001. Thanks to participating in a clinical trial, she receives advanced treatment that has allowed her to live with the disease in a manageable way for over 20 years! Read the full story: https://www.komen.org/blog/jerris-story-living-with-stage-4-inflammatory-breast-cancer/
🔍 **Want to know more about how a clinical trial can help you?**
** Contact us at www.trial-in.com
** Ask questions in the comments** 💬: We are happy to answer any questions!
** Share the post** 🔄: It might save someone’s life!
Remember, with metastatic disease, we are here for you.
Yours,
Nir Erez / Trial-In Pharma 💙
